Autoimmune diabetes induced by PD-1 inhibitor—retrospective analysis and pathogenesis: a case report and literature review

Cancer Immunology, Immunotherapy

Volumn 66, Issue 11, 2017, Pages 1399-1410

  Gauci, Marie Léa ^a,b   Laly, Pauline ^a,b   Vidal Trecan, Tiphaine ^d,e   Baroudjian, Barouyr ^a,b   Gottlieb, Jérémy ^a,b   Madjlessi Ezra, Nika ^a,b   Da Meda, Laetitia ^a,b   Madelaine Chambrin, Isabelle ^a,b   Bagot, Martine ^a,b   Basset Seguin, Nicole ^a,b   Pages, Cécile ^a,b   Mourah, Samia ^a,b   Boudou, Philippe ^a,c   Lebbé, Céleste ^a,b   Gautier, Jean François ^d,e  

^a SAINT LOUIS HOSPITAL   (France)

^b INSERM   (France)

^c UNIVERSITÉ PARIS DESCARTES   (France)

^d HÔPITAL LARIBOISIÈRE   (France)

^e CENTRE DE RECHERCHE DES CORDELIERS   (France)

Author keywords

Adverse events; Anti PD 1 antibody; Autoimmune diabetes; Melanoma

Indexed keywords

ALPHA INTERFERON; AUTOANTIBODY; B RAF KINASE; BICARBONATE; CARBIMAZOLE; COBIMETINIB; CREATININE; GLUCOSE; HEMOGLOBIN A1C; INSULIN; KETONE; NIVOLUMAB; VEMURAFENIB; MONOCLONAL ANTIBODY; PDCD1 PROTEIN, HUMAN; PROGRAMMED DEATH 1 RECEPTOR;

ABDOMINAL PAIN; ACUTE KIDNEY FAILURE; ADJUVANT THERAPY; AGED; ARTICLE; ASTHENIA; AUTOIMMUNE DISEASE; BODY MASS; CANCER ADJUVANT THERAPY; CANCER GROWTH; CANCER SURGERY; CASE REPORT; CLINICAL ARTICLE; COMBINATION DRUG THERAPY; CREATININE BLOOD LEVEL; CUTANEOUS MELANOMA; DYSLIPIDEMIA; EMERGENCY WARD; EXCISION; GENE MUTATION; GLUCOSE BLOOD LEVEL; GRAVES DISEASE; HEMOGLOBIN BLOOD LEVEL; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN TREATMENT; LOW DRUG DOSE; MALE; MEDICAL HISTORY; METABOLISM; METASTATIC MELANOMA; MOLECULARLY TARGETED THERAPY; POLYDIPSIA; POLYURIA; POSITRON EMISSION TOMOGRAPHY-COMPUTED TOMOGRAPHY; PRIORITY JOURNAL; RESPONSE EVALUATION CRITERIA IN SOLID TUMORS; RETROSPECTIVE STUDY; TREATMENT DURATION; URINALYSIS; URINARY DIPSTICK TEST; VOMITING; BLOOD; CHEMICALLY INDUCED; IMMUNOLOGY; MELANOMA; SKIN NEOPLASMS;

AGED; ANTIBODIES, MONOCLONAL; AUTOANTIBODIES; DIABETES MELLITUS, TYPE 1; HUMANS; MALE; MELANOMA; PROGRAMMED CELL DEATH 1 RECEPTOR; RETROSPECTIVE STUDIES; SKIN NEOPLASMS;

EID: 85021110198     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-017-2033-8     Document Type: Article

References (25)

1. Robert C, Long GV, Brady B et al (2015) Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med 372:320–330. doi:10.1056/NEJMoa1412082
2. Wang J, Yoshida T, Nakaki F et al (2005) Establishment of NOD-Pdcd1−/− mice as an efficient animal model of type I diabetes. Proc Natl Acad Sci USA 102:11823–11828. doi:10.1073/pnas.0505497102
3. Rajasalu T, Brosi H, Schuster C et al (2010) Deficiency in B7–H1 (PD-L1)/PD-1 coinhibition triggers pancreatic β-cell destruction by insulin-specific, murine CD8 T-cells. Diabetes 59:1966–1973. doi:10.2337/db09-1135
4. Guleria I, Gubbels Bupp M, Dada S et al (2007) Mechanisms of PDL1-mediated regulation of autoimmune diabetes. Clin Immunol 125:16–25. doi:10.1016/j.clim.2007.05.013
5. Hansen E, Sahasrabudhe D, Sievert L (2016) A case report of insulin-dependent diabetes as immune-related toxicity of pembrolizumab: presentation, management and outcome. Cancer Immunol Immunother 65:765–767. doi:10.1007/s00262-016-1835-4
6. Martin-Liberal J, Furness AJS, Joshi K et al (2015) Anti-programmed cell death-1 therapy and insulin-dependent diabetes: a case report. Cancer Immunol Immunother 64:765–767. doi:10.1007/s00262-015-1689-1
7. Mellati M, Eaton KD, Brooks-Worrell BM et al (2015) Anti-PD-1 and anti-PDL-1 monoclonal antibodies causing type 1 diabetes. Diabetes Care 38:e137–e138. doi:10.2337/dc15-0889
8. Hughes J, Vudattu N, Sznol M et al (2015) Precipitation of autoimmune diabetes with anti-PD-1 immunotherapy. Diabetes Care 38:e55–e57. doi:10.2337/dc14-2349
9. Gaudy C, Clévy C, Monestier S et al (2015) Anti-PD1 pembrolizumab can induce exceptional fulminant type 1 diabetes. Diabetes Care 38:e182–e183. doi:10.2337/dc15-1331
10. Munakata W, Ohashi K, Yamauchi N, Tobinai K (2017) Fulminant type I diabetes mellitus associated with nivolumab in a patient with relapsed classical Hodgkin lymphoma. Int J Hematol 105:383–386. doi:10.1007/s12185-016-2101-4
11. Teramoto Y, Nakamura Y, Asami Y et al (2017) Case of type 1 diabetes associated with less-dose nivolumab therapy in a melanoma patient. J Dermatol 44:605–606. doi:10.1111/1346-8138.13486
12. Miyoshi Y, Ogawa O, Oyama Y (2016) Nivolumab, an anti-programmed cell death-1 antibody, induces fulminant type 1 diabetes. Tohoku J Exp Med 239:155–158. doi:10.1620/tjem.239.155
13. Okamoto M, Okamoto M, Gotoh K et al (2016) Fulminant type 1 diabetes mellitus with anti-programmed cell death-1 therapy. J Diabetes Investig 7:915–918. doi:10.1111/jdi.12531
14. Hofmann L, Forschner A, Loquai C et al (2016) Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy. Eur J Cancer 60:190–199. doi:10.1016/j.ejca.2016.02.025
15. Aleksova J, Lau PKH, Soldatos G, McArthur G (2016) Glucocorticoids did not reverse type 1 diabetes mellitus secondary to pembrolizumab in a patient with metastatic melanoma. BMJ Case Rep 2016:2016217454. doi:10.1136/bcr-2016-217454
16. Lowe JR, Perry DJ, Salama AKS et al (2016) Genetic risk analysis of a patient with fulminant autoimmune type 1 diabetes mellitus secondary to combination ipilimumab and nivolumab immunotherapy. J Immunother Cancer 4:89. doi:10.1186/s40425-016-0196-z
17. Usui Y, Udagawa H, Matsumoto S et al (2017) Association of serum anti-GAD antibody and HLA haplotypes with type 1 diabetes mellitus triggered by nivolumab in patients with non-small cell lung cancer. J Thorac Oncol 12:e41–e43. doi:10.1016/j.jtho.2016.12.015
18. Chae YK, Chiec L, Mohindra N et al (2017) A case of pembrolizumab-induced type-1 diabetes mellitus and discussion of immune checkpoint inhibitor-induced type 1 diabetes. Cancer Immunol Immunother 66:25–32. doi:10.1007/s00262-016-1913-7
19. Ishikawa K, Shono-Saito T, Yamate T et al (2017) A case of fulminant type 1 diabetes mellitus, with a precipitous decrease in pancreatic volume, induced by nivolumab for malignant melanoma: analysis of HLA and CTLA-4 polymorphisms. Eur J Dermatol 27:184–185. doi:10.1684/ejd.2016.2923
20. Imagawa A, Hanafusa T, Miyagawa JI et al (2000) A novel subtype of type 1 diabetes mellitus characterized by a rapid onset and an absence of diabetes-related antibodies. N Engl J Med 342:301–307. doi:10.1056/NEJM200002033420501
21. Moreau C, Drui D, Arnault-Ouary G et al (2008) Fulminant type 1 diabetes in Caucasians: a report of three cases. Diabetes Metab 34:529–532. doi:10.1016/j.diabet.2008.05.003
22. Imagawa A, Hanafusa T, Awata T et al (2012) Report of the committee of the Japan Diabetes Society on the research of fulminant and acute-onset type 1 diabetes mellitus: new diagnostic criteria of fulminant type 1 diabetes mellitus (2012). J Diabetes Investig 3:536–539. doi:10.1111/jdi.12024
23. Lampasona V, Liberati D (2016) Islet autoantibodies. Curr Diab Rep 16:53. doi:10.1007/s11892-016-0738-2
24. Kochupurakkal NM, Kruger AJ, Tripathi S et al (2014) Blockade of the programmed death-1 (PD1) pathway undermines potent genetic protection from type 1 diabetes. PLoS ONE 9:e89561. doi:10.1371/journal.pone.0089561
25. Fujisawa R, Haseda F, Tsutsumi C et al (2015) Low programmed cell death-1 (PD-1) expression in peripheral CD4(+) T cells in Japanese patients with autoimmune type 1 diabetes. Clin Exp Immunol 180:452–457. doi:10.1111/cei.12603